Cardiff Oncology, Inc. (FRA:XE7C)

Market Cap	90.94M -53.5%
Revenue (ttm)	455.33K -10.6%
Net Income	-38.84M
EPS	-0.58
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.295
Previous Close	1.206
Day's Range	1.295 - 1.295
52-Week Range	1.126 - 3.760
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: XE7C

Financial Performance

In 2025, Cardiff Oncology's revenue was $593,000, a decrease of -13.18% compared to the previous year's $683,000. Losses were -$45.88 million, 0.93% more than in 2024.

Financial numbers in USD